MAPK3 and acute myeloid leukemia: The enhanced antileukemic activity of trametinib plus midostaurin suggests that simultaneous inhibition of the ERK1/2 pathway and FLT3 signaling (wild-type or mutated) might be an effective treatment strategy for AML patients.